Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

A Case Report of Bisphosphonate-induced Bilateral Osteoporotic Subtrochanteric Fracture Femurii: Review of Literature.

Uppin R, Gupta S, Prakash S.

J Orthop Case Rep. 2016 Sep-Oct;6(4):31-34. doi: 10.13107/jocr.2250-0685.558.

2.

Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.

Eisenstein N, Kasavkar G, Bhavsar D, Khan FS, Paskins Z.

BMC Musculoskelet Disord. 2017 Jan 23;18(1):29. doi: 10.1186/s12891-017-1392-9.

3.

Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use.

Higgins M, Morgan-John S, Badhe S.

J Orthop. 2016 Aug 12;13(4):401-3. doi: 10.1016/j.jor.2016.07.007.

PMID:
27570414
4.

Novel advances in the treatment of osteoporosis.

Chan CK, Mason A, Cooper C, Dennison E.

Br Med Bull. 2016 Sep;119(1):129-42. doi: 10.1093/bmb/ldw033. Review.

PMID:
27558130
5.

The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women.

Mobini M, Dehghan L, Yosefi G, Mohammadpour A, Abdi R.

Med J Islam Repub Iran. 2016 Feb 15;30:328.

6.

Management of atypical femoral fracture: a scoping review and comprehensive algorithm.

Toro G, Ojeda-Thies C, CalabrĂ² G, Toro G, Moretti A, Guerra GM, Caba-Doussoux P, Iolascon G.

BMC Musculoskelet Disord. 2016 May 23;17:227. doi: 10.1186/s12891-016-1086-8.

7.

Recommendations for preventing fracture in long-term care.

Papaioannou A, Santesso N, Morin SN, Feldman S, Adachi JD, Crilly R, Giangregorio LM, Jaglal S, Josse RG, Kaasalainen S, Katz P, Moser A, Pickard L, Weiler H, Whiting S, Skidmore CJ, Cheung AM; Scientific Advisory Council of Osteoporosis Canada..

CMAJ. 2015 Oct 20;187(15):1135-44, E450-61. doi: 10.1503/cmaj.141331. English, French. No abstract available.

8.

Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications.

Saita Y, Ishijima M, Kaneko K.

Ther Adv Chronic Dis. 2015 Jul;6(4):185-93. doi: 10.1177/2040622315584114. Review.

9.

Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis.

Nuti R.

Clin Cases Miner Bone Metab. 2014 Sep;11(3):208-14. Review.

10.

Pathological pelvic fracture following long-term bisphosphonate use in a 63-year-old woman.

Watson HI, Hopper GP, Gupta S, Roberts JL.

BMJ Case Rep. 2014 Oct 13;2014. pii: bcr2014206319. doi: 10.1136/bcr-2014-206319.

11.

Questioning the association between bisphosphonates and atypical femoral fractures.

Pazianas M, Kim SM, Yuen T, Sun L, Epstein S, Zaidi M.

Ann N Y Acad Sci. 2015 Jan;1335:1-9. doi: 10.1111/nyas.12551. Review.

12.

Acute nontraumatic clavicle fracture associated with long-term bisphosphonate therapy.

Vun SH, Husami Y, Shareef S, Bramley D.

Case Rep Orthop. 2014;2014:986718. doi: 10.1155/2014/986718.

13.

Long term bisphosphonate therapy & atypical femoral fractures: a word of caution.

Reddy SV.

Indian J Med Res. 2014 Jul;140(1):8-10. No abstract available.

14.

Bone anabolics in osteoporosis: Actuality and perspectives.

Montagnani A.

World J Orthop. 2014 Jul 18;5(3):247-54. doi: 10.5312/wjo.v5.i3.247. Review.

15.

Pharmacological management of osteogenesis.

Nardone V, D'Asta F, Brandi ML.

Clinics (Sao Paulo). 2014 Jun;69(6):438-46. Review.

16.

Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ.

Yoshiga D, Nakamichi I, Yamashita Y, Yamamoto N, Yamauchi K, Nogami S, Kaneuji T, Mitsugi S, Tanaka K, Kataoka Y, Sakurai T, Kiyomiya H, Miyamoto I, Takahashi T.

J Clin Exp Dent. 2014 Feb 1;6(1):e22-8. doi: 10.4317/jced.51213.

17.

A case report of long-term bisphosphonate therapy and atypical stress fracture of bilateral femur.

Jo YR, Kim HW, Moon SH, Ko YJ.

Ann Rehabil Med. 2013 Jun;37(3):430-2. doi: 10.5535/arm.2013.37.3.430.

18.

A review of periprosthetic femoral fractures associated with total hip arthroplasty.

Marsland D, Mears SC.

Geriatr Orthop Surg Rehabil. 2012 Sep;3(3):107-20. doi: 10.1177/2151458512462870.

19.

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ, Samaras AT, Fisher MJ, West DP, Langman CB, Stern PH.

J Bone Joint Surg Am. 2013 Feb 20;95(4):297-307. doi: 10.2106/JBJS.K.01181. Review.

20.

Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures.

Napoli N, Schwartz AV, Palermo L, Jin JJ, Wustrack R, Cauley JA, Ensrud KE, Kelly M, Black DM.

J Clin Endocrinol Metab. 2013 Feb;98(2):659-67. doi: 10.1210/jc.2012-1896.

Items per page

Supplemental Content

Support Center